HENDERSON, NV / ACCESSWIRE / July 23, 2015 / Quest Solution, Inc. (OTCBB: QUES), a leading provider in the technology, software, and mobile data collection systems business (the “Company”), today released preliminary revenues for the second quarter of its fiscal year 2015, ending June 30, 2015 (2Q 2015).

Mr. Tom Miller, Chief Executive Officer of the Company, indicated: “In order to release timely financial information to our stockholders, we are releasing preliminary revenues for 2Q 2015. Earnings will not be released until just prior to the filing of our quarterly report on Form 10-Q. We expect to file our 10-Q with the U.S. Securities and Exchange Commission on or before the August 15, 2015 deadline.”

Revenues reported for both the three and six months ended June 30, 2015 incorporate total bookings revenue, which allows for comparison to the prior year period where service contracts were fully recorded in the quarter they were signed. Beginning in Q1 2015, the Company began spreading service revenue recognition throughout the life of the contract. The estimated deferred service contract revenue as of June 30, 2015 is approximately $6.85 million with corresponding service contract cost and commission of $6 million, for approximately $850,000 which would have been added to the adjusted pro forma EBITDA for the six months ended June 30, 2015 but is now spread over the life of the contracts. The Company anticipates this number to continue to grow through the end of 2015 with the increases being offset by revenue being recognized in 2016.

Preliminary Results for Q2 2015:

– Preliminary net GAAP revenues for the three months ended June 30, 2015 increased approximately to $13.5 million which represents a 26% sequential increase compared to Q1 2015 of $10.7 million.
– Accounts receivable grew to approximately $9.7 million as of June 30, 2015 from approximately $8.5 million as of March 31, 2015.

Preliminary Results for the Six months ended June 30, 2015:

– Preliminary net revenues for the six months ended June 30, 2015 were approximately $24 million.
– Gross margin is anticipated to be approximately 22%, year to date.
– Business outlook and activity for the year remains strong re-affirms its full year FY2015 guidance of Booked Revenue between $62-$68 million, representing top line growth between 5-15% and generating positive adjusted EBITDA in the second quarter, with sequential improvement each quarter for the remainder of the year.

Operational Highlights:

– Quest Total Solutions as a Service (QTSaaS) model which the Company recently announced, has received a great initial response from our customers and the Company is working with additional vendors to grow this product offering.
– In December 2014, the Company announced the expansion of their sales force into New York and Chicago. The Company has been pleased with the growth it has achieved in these markets and are in the process of bringing on additional sales support and engineers in its Chicago location within the next 30 days.
– The Company’s due diligence process with the previously announced Viascan acquisition is moving forward and the Company anticipates closing the transaction in the third quarter of 2015. Viascan is expected to contribute incremental revenue of $22-$25 million (USD) and be accretive to Adjusted EBITDA.

The Company also announced that as the reporting period for the quarter end approaches it will be announcing the date, time and call in number for the quarterly investor conference call.

About Quest Solution, Inc.

Quest Solution, Inc. is a leading provider in the technology, software, and mobile data collection systems business. In November 2014, the Company announced that Bar Code Specialties, Inc. (BCS) joined with Quest Solution, Inc. The Company intends on continuing to acquire existing companies with revenues and positive cash flow.

Quest Solution, Inc. serves as a national mobility systems integrator with a focus on design, delivery, deployment and support of fully integrated mobile solutions. The Company takes a consultative approach by offering end to end solutions that include hardware, software, communications and full lifecycle management services. The highly tenured team of professionals simplifies the integration process and delivers proven problem solving solutions backed by numerous customer references.

Quest Solution Investor Relations & Financial Media:

Hayden IR
Brett Maas
(646) 536-7331
brett@haydenir.com

Cameron Donahue
(651) 653-1854
cameron@haydenir.com

SOURCE: Quest Solution, Inc.

ReleaseID: 430785

CORAL GABLES, FL / ACCESSWIRE / July 23, 2015 / Since July 2010, the iShares Nasdaq Biotechnology ETF (IBB) has gained more than 370%, rising from $77 on July 12, 2010 to June 2015 highs of $377 a share. A number of leading news media outlets are starting to report that we are in the midst of a biotech bubble, and that this bubble looks set to burst before the end of the year. This is not to say, however, that there are not opportunities in the space going forward.

Biotech is a strange sector in the sense that, while its constituent companies are not immune to a downturn in equities markets, we will often see a muted impact on event-driven stocks in particular, for two reasons. First, because biotechs undergoing imminent milestones are exceptional cases that are less impacted by beta conditions, and second, because biotech in general is becoming more and more of a public sector good with government involvement in the healthcare system. Much like defense stocks are insulated somewhat from the broader market and respond more strongly to defense spending developments, biotech as a whole will tend to move with healthcare spending developments as government becomes more and more involved.

On the chance that biotech is at an intermediate top at least, investors can look for further protection in the orphan drug space, which has a rhythm all its own. There are a number of companies that look promising in this arena, despite the looming fear that the biotech bull-run may have come to an end. Here we will look at a selection of these companies, what they bring to the table, and what we can expect from each going forward.

Lion Biotechnologies

Lion Biotechnologies (NADAQ:LBIO) is new to the orphan drug world, having just received orphan status from the FDA on June 11 for its novel metastatic melanoma treatment. The theory behind Lion’s lead candidate is what’s known as TIL’s, or tumor infiltrating lymphocytes. TIL’s are the body’s initial response to attacking cancer, and are present in solid tumors as a natural immune response. However, since cancer cells suppress the immune system in various ways, the TIL’s are ineffective after a short period of time.

Lion takes the TIL’s from a resected tumor and grows them in vitro. It then tests the cells response to the tumor antigen of the patient and selects the samples that have the best response to the antigen. Once the best candidates are selected, they are rapidly grown and then reinfused into the patient after the patient has undergone lymphodepleting treatment. A lymphodepleting treatment basically erases the patient’s current immune cells, making the cells reintroduced the dominant ones in the immune system and in effect more powerful.

In phase 2 trials, patients were given their own TIL’s after lymphodepletion and various levels of total body radiation. Researchers found that the more radiation given, the higher the response rate to the TIL’s proved to be. 20 patients out of 93 showed a complete response to therapy, and the proportion of complete responders in the cohort that was administered the highest radiation dose before therapy was a very high 40%.

Lion will be initiating a phase 3 trial for its orphan candidate this year, and results so far look very promising.

Protalex

Protalex (PRTX) announced on June 16 that the FDA granted orphan drug designation to one of its candidates called PRTX-100 – targeted at the treatment of immune thrombocytopenia (“ITP”). PRTX-100 is the company’s lead product, and has already demonstrated safety, tolerability, and acceptable pharmacokinetics across five different clinical studies at a range of dose levels.

So how does it work? First, it’s important to understand what ITP is. In patients that suffer from ITP, blood clotting does not work as it should. This derives from a reduced number of a type of blood cell fragment called platelets, and can lead to severe blood loss through minor injury, as well as heavy bruising. It is similar to hemophilia in symptoms, but the cause is different .Hemophiliacs lack clotting factors, while thrombocytopeniacs lack platelets.

One of the reasons for the lack of platelets is auto-antibodies, or the patient’s own immune system binding to the platelets and signaling them as targets. Rhis means that the immune system disposes of platelets. PRTX-100 inhibits immune system action against platelets, and in doing so, can raise or at least stabilize the number platelets in a patient’s system. A stabilized platelet count translates to better clotting and a reduction in severity of ITP.

How have trials looked so far? Phase 1 trials have already supported safety and tolerability, and Protalex is now looking to initiate enrolment for a range of Phase I/II clinical trials in the coming quarter. Topline data from the trial is expected during the second half of 2016. It is worth mentioning that the current standard of care treatments for ITP increase production of platelets, but reportedly do not affect the platelet destruction process. PRTX-100 has shown so far that it can reduce platelet destruction, and this could set it aside from the competition on approval.

Retrophin

Retrophin (NASDAQ:RTRX) is yet another biotech specializing in Orphan drugs. Retrophin is one of the best performing stocks in 2015, and continues to climb, having just passed $1B in market cap, rising 185% year to date. Retrophin already has 3 orphan drugs on the market, one more in the clinical phase, and 2 others preclinical. It only began seeing revenues last year, but has a long way to go before being consistently profitable. This growth comes despite the company getting some negative press due to firing its CEO last year. If anything Retrophin shows the full potential of the orphan drug space.

Lipocine Inc.

Lipocine (NASDAQ:LPCN) is also new to the orphan space, having received orphan status from the FDA for its preterm birth candidate on June 2. While most do not think of preterm birth as a significant unmet medical need, it is responsible for 75% of infant mortality cases in the US, occurring in 12% of all US births. Lipocine’s product is an oral formation of a type of progesterone that is injected intramuscularly that is already approved for this indication. Progesterone is otherwise known as the pregnancy hormone, and low levels of it can lead to preterm birth. Raising the level of progesterone, then, decreases the chances of premature birth.

The injectable progesterone formulation for preterm birth requires weekly injections at a doctor’s office, which disrupts daily life, not to mention that the injections are painful. Lipocine’s formulation is a twice daily pill, and has shown in phase 1 trials that the drug has high bioavailability and absorption and is expected to match the efficacy of the injectable formulation in upcoming efficacy trials, with no serious side effects.

It’s a simple concept for an indication that is often overlooked, but it could be a big deal if it shows superiority to injectable progesterone. With market exclusivity for 7 years upon approval, Lipocine’s product could be quite a hit, significantly lowering the cost of neonatal intensive care across the country.

Matinas BioPharma

Lastly is Matinas BioPharma Holdings, Inc. (OTCMKTS:MTNB). And this might be the most exiting one with serious potential given its lead candidate. In January this year, we learned that Matinas had acquired all the outstanding stock of Aquarius BioTechnologies Inc., and along with it, a number of promising candidates with a range of NIH grants already in place. The most advanced of this pipeline is CAmB, now referred to as MAT2203. MAT2203 is an orally administered variation on a current broad-spectrum fungicidal, Amphotericin B, which is currently administered intravenously. The current IV variation has significant negative side effects associated with it that make the drug only usable as a last resort. One of the more severe being nephrotoxicity (kidney poisoning). In a clinical Phase 1a single-dose trial conducted last year, the CAmB demonstrated a positive tolerability profile, with no adverse events reported across 48 healthy volunteers when orally administrated. This is because the Amphotericin B is housed in a lipid envelope, shielding the body from side effects.

Matinas’ other lead candidate was recently in the news for passing a Phase 1 comparison study with flying colors. MAT9001 was compared with current best-in-class Vascepa for dyslipidemia, or very high triglycerides. Since this candidate has an overlap with cholesterol-lowering statins, it has the potential to compete with all time best selling drug Lipitor in a best case scenario.

Matinas intends to carry MAT2203 forward into a Phase 2a trial, funded by the NIH, before the end of this year. Once again, this is a small company, and as such, a risky allocation. However, much of this risk is mitigated by the fact that all of Matinas’ acquired pipeline have pre-arranged funding through NIH grants, meaning (and as Matinas has publicly stated) there should be no material increase in the company’s cash burn short-term as a result of the transaction. Funding is often a huge risk factor in development stage biotech’s, but in this instance, it need not be perhaps quite as serious a consideration as it might be with other potential portfolio allocations.

About Biotech Stocks (www.BiotechStocks.com)

Biotech Stocks (www.biotechstocks.com) is your best resource for today’s emerging biotech industry. Whether you’re looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to.

Contact Info:

Email:info@biotechstocks.com
URL: www.BiotechStocks.com

SOURCE: BioTechStocks.com

ReleaseID: 430783

The New and Improved Website from A Better Bit Offers Horse Owners and Trainers an Easier Shopping and Selection Experience Across all Myler Bits

DENVER, CO / ACCESSWIRE / July 23, 2015 / A Better Bit, a leading equestrian online store for horse owners and trainers, announced a newly updated and improved website, abetterbit.com. The website offers visitors a better shopping experience with an intuitive interface that makes finding the right product easier and quicker. In addition, A Better Bit is offering a 10 percent discount on their products with complimentary U.S. shipping on all orders and discounted shipping rates to the United Kingdom and Australia.

“At A Better Bit, we are first and foremost horse riders, owners and caretakers,” said the company’s spokesperson. “Our new website offers customers an improved online experience and supports our company’s stated mission, which is to put the safety and care of our customer’s horses above all else.”

Customer service is also a high priority for A Better Bit. Every interaction with the company’s expert staff provides customers with clear communication, transparency and honesty.

According to the website, the reason that they started the company was because of their passion for Myler bits.

“Our horses preformed better, were more comfortable and easy-going, and riding them became more pleasurable when we got them all on Myler bits,” said the company’s spokesperson. “We decided to start A Better Bit with the simple goal of making it easy for any rider to get a Myler bit no matter where they lived or cared for their horses.”

The professionals at A Better Bit know that finding the right bit for a horse can be challenging. They wanted to make the bit selection process as simple as possible.

A Better Bit recommends snaffle bits, which are bits that apply direct pressure and do not use leverage. In other words, the amount of pressure a rider exerts on the bit is exactly the same pressure applied to the horse’s mouth. This completely prevents pinching of the lips and bars, which the creators of the Myler bitting system believe is unnecessary to train a horse.

About A Better Bit

A Better Bit is an online horse riding product store that offer horse owners and trainers an easy way to fond the best Myler bit for their horse. For more information, please visit http://abetterbit.com.

Contact:

Matt Herbert
contact@abetterbit.com
1 (855) 9799-BIT

SOURCE: A Better Bit

ReleaseID: 430792

HOUSTON, TX / ACCESSWIRE / July 23, 2015 / Gerald B. Hammack, President of Valmie Resources Inc. (OTCMKTS: VMRI) today commented on the Association for Unmanned Vehicle Systems’ (AUVSI) recommendations for industry-wide best practices for small drones in the commercial sector throughout the National Airspace System.

“AUVSI’s recommendations mirror a worldwide trend that has been demonstrated in countries with established and robust commercial drone enterprises,” said Hammack. “AUVSI teamed up with technical and industry leaders to develop the recommendations, which ensure implementation of safe and efficient operations and a more adaptable working environment. The implementation of these proposed rules will encourage innovations and lead to improvement and benefits in many other sectors.”

In response to the Federal Aviation Administration’s (FAA) notice of proposed rulemaking in February, AUVSI called for a “risk-based, technology-neutral approach” to the use of small unmanned aerial vehicles (UAV’s) – defined as aircraft weighing less than 55 pounds. It calls for a more flexible operating environment, including nighttime, beyond line-of-sight and multiple UAV flights.

This approach would allow for aerial surveys above rural farmland, flare stack and bridge inspections, assessment of damage following natural disasters, and other uses that save lives and keep people out of dangerous areas. Under this scenario, operators and manufacturers could use a variety of technologies and best practices to meet necessary safety requirements instead of being forced to employ mandated technologies.

Among other recommendations, this method would require the FAA to review a number of aspects in a UAV operation to establish the operation’s risk value. If the risk value is determined to be below an acceptable limit, it would be considered as safe, regardless of the specific technology used.

“AUVSI’s proposed framework will prevent the stunting of this growing sector in the U.S. Non-line-of-sight and nighttime operations will usher in a giant stride for this emerging industry,” said Hammack.

About Valmie Resources (OTCMKTS:VMRI)

Valmie Resources is a U.S. company actively pursuing opportunities for the commercialization of leading edge products and services in the rapidly expanding technology industry. Valmie seeks concepts with valid business models positioned to make a significant impact within the four key “megasectors” of technology: software, hardware, networking and semiconductors. Valmie brings operating talent, tools and leadership to emerging companies in these sectors, promoting industry awareness and developing economically sustainable partnerships while increasing shareholder value.

For further information visit http://valmie.com.

Forward-Looking Statements

Certain information provided in this press release constitutes forward-looking statements. The words “anticipate,” “expect,” “project,” “estimate,” “forecast” and similar expressions are intended to identify such forward-looking statements. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be incorrect. Actual results achieved during the forecast period will vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. You can find a discussion of those risks and uncertainties in our EDGAR securities filings with the Securities and Exchange Commission. Such factors include, but are not limited to: general economic, market and business conditions; fluctuations in the technology market; the results of product development and the result of our efforts to develop strategic relationships, partnerships and potential acquisitions that are in line with our business model; outcome of partnership negotiations; the uncertainty of market estimates; changes in environmental and other regulations; risks associated with retail operations; and other factors, many of which are beyond the control of the Company. There is no representation by Valmie Resources that actual results achieved during the forecast period will be the same in whole or in part as those forecast. Except as may be required by applicable securities laws, Valmie Resources assumes no obligation to publicly update or revise any forward-looking statements made herein or otherwise, whether as a result of new information, future events or otherwise.

Contact:

Valmie Resources, Inc.
Gerald B. Hammack, President and CEO
713-595-6675

SOURCE: Valmie Resources, Inc.

ReleaseID: 430789